Session All Listing

Session Title	Start Time	End Time
Registration & Breakfast	5/5/2022 8:30 AM	5/5/2022 9:00 AM
Welcome and Board Activities	5/5/2022 9:00 AM	5/5/2022 9:30 AM
Keynote Address: From Reading The Genome For Risk To Rewriting It For Cardiovascular Health	5/5/2022 9:30 AM	5/5/2022 10:15 AM
The Future of the State of Possible Amidst Rapid Expansion In 2021, Massachusetts biotech companies received $13.66 billion in venture capital funding. Combined with a successful IPO market in past years, our industry has the capital on-hand for significant growth. At the same time, companies are facing on-going hiring challenges at all levels but especially for experienced talent. This panel of experts from industry and academia will explore what Massachusetts needs to do both short- and longer-term to address the workforce gap so we can continue as the State of Possible for industry and for patients.	5/5/2022 10:15 AM	5/5/2022 11:00 AM
Networking Break	5/5/2022 11:00 AM	5/5/2022 11:15 AM
Innovative Leadership Award & Fireside Chat with Governor Deval Patrick With over 84,000 people working in biopharma jobs across Massachusetts, our industry is a significant part of the state’s economy. Issues beyond drug pricing such as housing, transportation, education, and childcare have significant impacts on the ability for life sciences companies to hire and retain workforce. Making improvements in these areas is critical for the on-going success of our industry and for the economic prosperity of Massachusetts and its residents. In this fireside chat, the panelists will discuss the role that the life sciences industry has in these debates, the potential solutions to some of these issues, and more.	5/5/2022 11:15 AM	5/5/2022 12:00 PM
Lunch	5/5/2022 12:00 PM	5/5/2022 1:15 PM
The Next “Massachusetts Miracle:” A Biotech-Led Effort to Preempt Disease and Transform Human Health	5/5/2022 1:15 PM	5/5/2022 2:00 PM
So Your Biotech is Public, Now What? Across 2020 and 2021, 149 biotech companies went public nationally at offerings over $50 million. These companies continued a trend of more companies going public through an IPO earlier in their life-cycle – the median time from founding to IPO has gone from 10 years in 2013 to only 4 years in 2021. Going public is a major milestone, but much lies ahead. This panel of experts will discuss life after after an IPO, especially during the current market downturn.	5/5/2022 2:00 PM	5/5/2022 2:45 PM
The COVID Vaccine & Therapeutics Development's Effect on Future Drug Development & DCT's There may never be another Operation Warp Speed, but are there strategies, tools, or tactics utilized during the rapid development of the COVID-19 vaccines and therapeutics that can be applied to drug development in other areas going forward? This panel of experts will explore that question and seek to identify how the drug development process can be improved to get new, safe and effective therapies and cures to patients faster.	5/5/2022 2:00 PM	5/5/2022 2:45 PM
Innovation and Access in Mental Health Care Massachusetts Blue Cross Blue Shield Foundation recently released survey findings that more than 1 in 3 adults reported needing behavioral health care for themselves or a family member over the last 12 months but only 1 in 4 received care. Despite advancements in science, medicine, and technology in mental health care over the past 20 years, a significant gap remains in brain health. This panel will discuss the recent discoveries in mental health care delivery, access, and innovation including drug discovery and development, new medication management tools, telepsychiatry, and digital therapeutics.	5/5/2022 2:45 PM	5/5/2022 3:30 PM
Global Supply Chain Challenges, What does 2022 and Beyond Look Like? Global supply chain disruptions are impacting every piece of the economy and the life sciences is no exception. From unavailability to longer lead times to significant price increases, life sciences companies are being forced to reckon with new levels of uncertainty that can impact business operations and business strategies. This panel will discuss how global supply chain disruptions have impacted their organization, how they have reacted, and how they are planning for the future.	5/5/2022 2:45 PM	5/5/2022 3:30 PM
Networking Break	5/5/2022 3:30 PM	5/5/2022 3:45 PM
Beyond the CEO Pledge, Where are we Now? In this panel we will hear directly from member companies who signed MassBio’s CEO Pledge for a More Equitable and Inclusive Life Sciences Industry about their approach to meeting the pledge’s six commitments around improving DEI at their organization. The wide-ranging discussion will cover areas such as leadership and executive culture, inclusive company culture, recruitment & retention, and supplier diversity.	5/5/2022 3:45 PM	5/5/2022 4:30 PM
Next Generation Therapeutics The panel, “Next Generation Therapeutics,” will explore the therapeutics landscape as it continues to break new ground. In Massachusetts we have had a front row seat to the extraordinary success of the mRNA COVID-19 vaccines happening in real time on the world stage. As we come off an unprecedented year and look to the future, forecasts are predicting growth from a market of $5 billion in 2020 to $58 billion in 2026, according to the Evaluate Pharma consensus. Panelists will share the latest trends they are seeing, what therapies are experiencing rapid growth, who are the therapeutic leaders, and how the landscape will evolve over the next 12 months and the market respond.	5/5/2022 3:45 PM	5/5/2022 4:30 PM
Evening Event: Let's Celebrate the Biotech Community!	5/5/2022 5:00 PM	5/5/2022 8:00 PM

Brought to you by